- Home
- HKD vs REPL Comparison
HKD vs REPL Comparison
Compare HKD & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKD
- REPL
- Stock Information
- Founded
- HKD 2003
- REPL 2015
- Country
- HKD France
- REPL United States
- Employees
- HKD N/A
- REPL N/A
- Industry
- HKD Finance: Consumer Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- HKD Finance
- REPL Health Care
- Exchange
- HKD Nasdaq
- REPL Nasdaq
- Market Cap
- HKD 656.8M
- REPL 547.0M
- IPO Year
- HKD 2022
- REPL 2018
- Fundamental
- Price
- HKD $1.65
- REPL $5.67
- Analyst Decision
- HKD
- REPL Buy
- Analyst Count
- HKD 0
- REPL 10
- Target Price
- HKD N/A
- REPL $8.25
- AVG Volume (30 Days)
- HKD 209.0K
- REPL 17.2M
- Earning Date
- HKD 01-01-0001
- REPL 08-07-2025
- Dividend Yield
- HKD N/A
- REPL N/A
- EPS Growth
- HKD 9.93
- REPL N/A
- EPS
- HKD 0.23
- REPL N/A
- Revenue
- HKD $20,445,000.00
- REPL N/A
- Revenue This Year
- HKD N/A
- REPL N/A
- Revenue Next Year
- HKD N/A
- REPL $194.05
- P/E Ratio
- HKD $7.12
- REPL N/A
- Revenue Growth
- HKD N/A
- REPL N/A
- 52 Week Low
- HKD $1.57
- REPL $2.68
- 52 Week High
- HKD $5.80
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- HKD 44.97
- REPL 45.73
- Support Level
- HKD $1.57
- REPL $5.08
- Resistance Level
- HKD $1.69
- REPL $5.84
- Average True Range (ATR)
- HKD 0.07
- REPL 0.46
- MACD
- HKD 0.00
- REPL 0.17
- Stochastic Oscillator
- HKD 52.93
- REPL 62.11
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.